6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Author:

Earl Helena M,Hiller Louise,Vallier Anne-Laure,Loi Shrushma,McAdam Karen,Hughes-Davies Luke,Harnett Adrian N,Ah-See Mei-Lin,Simcock Richard,Rea Daniel,Raj Sanjay,Woodings Pamela,Harries Mark,Howe Donna,Raynes Kerry,Higgins Helen B,Wilcox Maggie,Plummer Chris,Mansi Janine,Gounaris Ioannis,Mahler–Araujo Betania,Provenzano Elena,Chhabra Anita,Abraham Jean E,Caldas Carlos,Hall Peter S,McCabe Christopher,Hulme Claire,Miles David,Wardley Andrew M,Cameron David A,Dunn Janet A,Agarwal Roshan,Algurafi Hafiz,Allerton Rozenn,Archer Caroline,Armstrong Anne,Bale Catherine,Barraclough Lisa,Barthakur Urmila,Bedi Carolyn,Benstead Kim,Bloomfield David,Bowen Rebecca,Bradley Chris,Brown Jane,Butt Mohammad,Churn Mark,Cleator Susan,Cliff Joanne,Crellin Perric,Daly Margaret,De Silva-Minor Shiroma,Dhadda Amandeep,Din Omar,Down Sue,Earl Helena,Eaton David,Eichholz Andrew,Epurescu Daniel,Goh Chee,Goodman Andrew,Grieve Robert,Hadaki Maher,Harper-Wynne Catherine,Harries Mark,Hayward Larry,Humphreys Alison,Innes Helen,Jafri Mariam,Jegannathen Apurna,Kelleher Muireann,Kristeleit Hartmut,Lee Daniela,Lupton Susan,MacGregor Carol,Malik Zafar,Mansi Janine,Marshall Jennifer,McAdam Karen,McGolick Trevor,Mehra Rakesh,Miles David,Mithal Natasha,Moss Charlotte,Moss Aian,Mukesh Mukesh,Neal Anthony,Nelmes Daniel,Neville-Webbe Helen,Newby Jacqueline,O'Reilly Susan,Ostler Peter,Persic Mojca,Pettit Laura,Raj Sanjay,Raja Fharat,Rea Daniel,Reed Catherine,Rigg Anne,Roe Helen,Shah Nihal,Simmonds Peter,Sims Eliot,Smith Sarah,Storey Nicola,Taylor Wendy,Thanvi Narottam,Tipples Karen,Vaidya Jayant,Varughese Mohini,Vinayan Anup,Walji Nawaz,Waters Simon,Woodings Pamela,Wright Kathryn,Yahya Sundus

Funder

National Institute of Health Research Health Technology Assessment Programme

Publisher

Elsevier BV

Subject

General Medicine

Cited by 221 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3